X

Trial Profile

Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jul 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions
Acronyms CheckMate 800
Sponsors Bristol-Myers Squibb

Most Recent Events

13 Oct 2021 Status changed from active, no longer recruiting to completed.
22 Dec 2018 Status changed from recruiting to active, no longer recruiting.
17 Oct 2017 Planned primary completion date changed from 12 Dec 2017 to 24 Nov 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com